Tanima Sarkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tanima Sarkar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ranu Biswas
Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, WB, India
4 shared publications - Leonard Ionut Atanase
Faculty of Medicine, Apollonia University of Iasi, 700055 Iasi, Romania
3 shared publications - Ahesan Ansari
Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, WB, India
2 shared publications - Shounak Sarkhel
Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata 700109, WB, India
2 shared publications - Sourav Mondal
Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, WB, India
2 shared publications - Alexandru Carauleanu
Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
1 shared publication
Latest Publications
- Open Access
- 12 June 2026
- Published by MDPI AG in Polysaccharides
- Vol. 7 (2) , 68
Mucoadhesive Biopolysaccharides as Potential Platform for Novel Delivery of Therapeutic Agents
Mucoadhesive drug delivery systems have emerged as a promising strategy to enhance the therapeutic efficacy of pharmaceuticals by improving drug residence time, bioavailability, and site-specific targeting. Among various materials investigated, biopolysaccharides have gained significant attention due to their biocompatibility, biodegradability, non-toxicity, and inherent mucoadhesive properties. Natural polymers such as chitosan, alginate, pectin, hyaluronic acid, and cellulose derivatives exhibit strong interactions with mucosal surfaces through hydrogen bonding, electrostatic interactions, and polymer chain entanglement. These properties enable prolonged drug retention at mucosal sites, controlled drug release, and enhanced permeation across biological barriers. Mucoadhesive biopolysaccharides have been explored for diverse routes of administration, including oral, buccal, nasal, ocular, vaginal, and pulmonary delivery. Furthermore, chemical modification and nanostructuring of these polymers have expanded their functionality, enabling targeted delivery of small molecules, proteins, peptides, and nucleic acids. This review highlights the mechanisms of mucoadhesion, key biopolysaccharides used in drug delivery, formulation approaches, and recent advances in their application as versatile platforms for novel therapeutic delivery systems. The continued development of mucoadhesive biopolysaccharide-based carriers holds substantial potential for improving treatment outcomes and patient compliance.
- 12 June 2026
- Published by MDPI AG in Polysaccharides
- Vol. 7 (2) , 68
Open AccessMucoadhesive Biopolysaccharides as Potential Platform for Novel Delivery of Therapeutic Agents
Mucoadhesive drug delivery systems have emerged as a promising strategy to enhance the therapeutic efficacy of pharmaceuticals by improving drug residence time, bioavailability, and site-specific targeting. Among various materials investigated, biopolysaccharides have gained significant attention due to their biocompatibility, biodegradability, non-toxicity, and inherent mucoadhesive properties. Natural polymers such as chitosan, alginate, pectin, hyaluronic acid, and cellulose derivatives exhibit strong interactions with mucosal surfaces through hydrogen bonding, electrostatic interactions, and polymer chain entanglement. These properties enable prolonged drug retention at mucosal sites, controlled drug release, and enhanced permeation across biological barriers. Mucoadhesive biopolysaccharides have been explored for diverse routes of administration, including oral, buccal, nasal, ocular, vaginal, and pulmonary delivery. Furthermore, chemical modification and nanostructuring of these polymers have expanded their functionality, enabling targeted delivery of small molecules, proteins, peptides, and nucleic acids. This review highlights the mechanisms of mucoadhesion, key biopolysaccharides used in drug delivery, formulation approaches, and recent advances in their application as versatile platforms for novel therapeutic delivery systems. The continued development of mucoadhesive biopolysaccharide-based carriers holds substantial potential for improving treatment outcomes and patient compliance.
- Open Access
- 1 July 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- p. 1-8
PHARMACEUTICAL POLYMERS IN DRUG DELIVERY: AN OVERVIEW
Polymers have significantly assisted to the advancement of the drug delivery devices by adjusting the drug release at consistent rates over extended durations, facilitating cyclic administration, and targeting to the desired site. Polymers are frequently utilized as taste-masking, stabilizing, and proactive agents. The key characteristics that render polymers appealing options for drug delivery include their safety, effectiveness, hydrophilicity, non-immunogenicity, biological inertness, favourable pharmaceutical kinetics, and the presence of functional groups that facilitate covalent crosslinking, targeting ligands, or copolymer formation. Natural polymers that are more commonly used, like arginine, collagen, chitosan, and carrageenans are discussed for their possible application in polymeric drug delivery systems. Synthetic polymers exhibit elevated immunogenicity, limiting their viability for prolonged application. Non-biodegradable polymers necessitate subsequent removal post-drug release at the intended site. Progress in polymer science has made possible in the emergence of various innovative drug delivery systems, including hydrogels, liposomes, nanoparticles, micelles, patches, implants, and others. Biodegradable polymers have garnered considerable interest because they can degrade into non-toxic monomers, enabling sustained drug release from biodegradable polymer-based controlled-release devices. This review delves into the commonly used synthetic and natural polymers that are used in drug delivery, consideration of selection of polymers and recent advancement in polymer research.
- 1 July 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- p. 1-8
Open AccessPHARMACEUTICAL POLYMERS IN DRUG DELIVERY: AN OVERVIEW
Polymers have significantly assisted to the advancement of the drug delivery devices by adjusting the drug release at consistent rates over extended durations, facilitating cyclic administration, and targeting to the desired site. Polymers are frequently utilized as taste-masking, stabilizing, and proactive agents. The key characteristics that render polymers appealing options for drug delivery include their safety, effectiveness, hydrophilicity, non-immunogenicity, biological inertness, favourable pharmaceutical kinetics, and the presence of functional groups that facilitate covalent crosslinking, targeting ligands, or copolymer formation. Natural polymers that are more commonly used, like arginine, collagen, chitosan, and carrageenans are discussed for their possible application in polymeric drug delivery systems. Synthetic polymers exhibit elevated immunogenicity, limiting their viability for prolonged application. Non-biodegradable polymers necessitate subsequent removal post-drug release at the intended site. Progress in polymer science has made possible in the emergence of various innovative drug delivery systems, including hydrogels, liposomes, nanoparticles, micelles, patches, implants, and others. Biodegradable polymers have garnered considerable interest because they can degrade into non-toxic monomers, enabling sustained drug release from biodegradable polymer-based controlled-release devices. This review delves into the commonly used synthetic and natural polymers that are used in drug delivery, consideration of selection of polymers and recent advancement in polymer research.
- Top Cited PapersOpen Access
Chitosan and Its Derivatives as Nanocarriers for Drug Delivery
Chitosan (CS) occurs naturally as an alkaline polysaccharide and has been demonstrated to have several activities of a biological nature. Additionally, as CS chains have functional hydroxyl and amino groups that are active, their applications can be expanded by chemically or molecularly altering the molecules to incorporate new functional groups. Due to its outstanding qualities, including biodegradability, biocompatibility, non-toxicity, and accessibility, it has received significant interest in all areas of biomedicine and nanomaterials being extremely promising as drug nanocarrier. The last decades have produced a lot of interest in CS-based nanoparticles (CSNPs), with an increasing number of research papers from around 1500 in 2015 to almost 5000 in 2024. The degree of crosslinking, the particulate system’s shape, size, and density, in addition to the drug’s physical and chemical properties, all have a role in how the drug is transported and released from CSNPs. When creating potential drug delivery systems based on CSNPs, all these factors must be considered. In earlier, CSNPs were employed to enhance the pharmacotherapeutics, pharmacokinetics, and solubility properties of drugs. By investigating its positively charged characteristics and changeable functional groups, CS has evolved into a versatile drug delivery system. The drug release from CSNPs will definitely be influenced by various changes to the functional groups, charges, and polymer backbone. This review mainly discusses the most important results published in the last decade. Despite the promising advantages of CSNPs, challenges related to the translation into clinical stages remain and further in vitro and in vivo studies are mandatory.
Top Cited PapersOpen AccessChitosan and Its Derivatives as Nanocarriers for Drug Delivery
Chitosan (CS) occurs naturally as an alkaline polysaccharide and has been demonstrated to have several activities of a biological nature. Additionally, as CS chains have functional hydroxyl and amino groups that are active, their applications can be expanded by chemically or molecularly altering the molecules to incorporate new functional groups. Due to its outstanding qualities, including biodegradability, biocompatibility, non-toxicity, and accessibility, it has received significant interest in all areas of biomedicine and nanomaterials being extremely promising as drug nanocarrier. The last decades have produced a lot of interest in CS-based nanoparticles (CSNPs), with an increasing number of research papers from around 1500 in 2015 to almost 5000 in 2024. The degree of crosslinking, the particulate system’s shape, size, and density, in addition to the drug’s physical and chemical properties, all have a role in how the drug is transported and released from CSNPs. When creating potential drug delivery systems based on CSNPs, all these factors must be considered. In earlier, CSNPs were employed to enhance the pharmacotherapeutics, pharmacokinetics, and solubility properties of drugs. By investigating its positively charged characteristics and changeable functional groups, CS has evolved into a versatile drug delivery system. The drug release from CSNPs will definitely be influenced by various changes to the functional groups, charges, and polymer backbone. This review mainly discusses the most important results published in the last decade. Despite the promising advantages of CSNPs, challenges related to the translation into clinical stages remain and further in vitro and in vivo studies are mandatory.
- Open Access
- 9 December 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (12) , 1572
Nanotechnology-Based Approaches for the Management of Diabetes Mellitus: An Innovative Solution to Long-Lasting Challenges in Antidiabetic Drug Delivery
Diabetes is a widespread metabolic illness. Mismanagement of diabetes can lead to severe complications that tremendously impact patients’ quality of life. The assimilation of nanotechnology in diabetes care holds the potential to revolutionize treatment paradigms, improve patient outcomes, and reduce the economic burden associated with this pervasive disease. This manuscript explores the multifaceted utilization of nanomaterials in diabetes care, emphasizing the unique features of nano-based medication delivery methods and smart drug delivery mechanisms. Additionally, this paper talks about research on nanocarrier-integrated oral, transdermal, and inhalable insulin delivery; dendrimer- and nanocarrier-coupled antisense oligonucleotide-driven gene therapy; the implementation of gold nanoparticles and quantum dots for glucose surveillance; and nucleic acid therapies. There are certain restrictions when using medication delivery methods that are commonly available to handle diabetes. In order to increase efficacy and safety, the rapidly developing science of nanotechnology is also being explored and employed in medical biology. Nanomaterials like liposomes, dendrimers, niosomes, polymeric and metallic nanocarriers, and solid lipid nanoparticles are among the nanocarriers that have been developed for better delivery of various oral hypoglycemic agents in comparison to conventional therapies. These nanocarriers provide great control over elevated blood glucose levels, making them one of the most intriguing and promising technologies available today. Furthermore, adding additional ligands to nanocarriers allows for more focused distribution while protecting the encapsulated hypoglycemic drugs.
- 9 December 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (12) , 1572
Open AccessNanotechnology-Based Approaches for the Management of Diabetes Mellitus: An Innovative Solution to Long-Lasting Challenges in Antidiabetic Drug Delivery
Diabetes is a widespread metabolic illness. Mismanagement of diabetes can lead to severe complications that tremendously impact patients’ quality of life. The assimilation of nanotechnology in diabetes care holds the potential to revolutionize treatment paradigms, improve patient outcomes, and reduce the economic burden associated with this pervasive disease. This manuscript explores the multifaceted utilization of nanomaterials in diabetes care, emphasizing the unique features of nano-based medication delivery methods and smart drug delivery mechanisms. Additionally, this paper talks about research on nanocarrier-integrated oral, transdermal, and inhalable insulin delivery; dendrimer- and nanocarrier-coupled antisense oligonucleotide-driven gene therapy; the implementation of gold nanoparticles and quantum dots for glucose surveillance; and nucleic acid therapies. There are certain restrictions when using medication delivery methods that are commonly available to handle diabetes. In order to increase efficacy and safety, the rapidly developing science of nanotechnology is also being explored and employed in medical biology. Nanomaterials like liposomes, dendrimers, niosomes, polymeric and metallic nanocarriers, and solid lipid nanoparticles are among the nanocarriers that have been developed for better delivery of various oral hypoglycemic agents in comparison to conventional therapies. These nanocarriers provide great control over elevated blood glucose levels, making them one of the most intriguing and promising technologies available today. Furthermore, adding additional ligands to nanocarriers allows for more focused distribution while protecting the encapsulated hypoglycemic drugs.